Loading
BNC / Healthy Volunteers · Phase 1 Trial
ClinicalTrials.gov · August 4, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 1 clinical trial registration for bisnorcymserine (BNC), a candidate Alzheimer's disease therapeutic, conducted in healthy older volunteers to assess safety, tolerability, and pharmacokinetics. Recruitment has completed with 75 participants enrolled, but no results have been posted to this registry record, so no efficacy, safety outcomes, or clinical conclusions can be drawn.
Phase 1, Interventional, Randomized, Parallel, Double masking, Treatment purpose. Healthy Volunteers; age from 55 Years. Intervention: BNC. Compared with: Placebo — Placebo Comparator. n = 75. 2 sites: United States.
This is a Phase 1 clinical trial registration for bisnorcymserine (BNC), a candidate Alzheimer's disease therapeutic, conducted in healthy older volunteers to assess safety, tolerability, and pharmacokinetics. Recruitment has completed with 75 participants enrolled, but no results have been posted to this registry record, so no efficacy, safety outcomes, or clinical conclusions can be drawn.
Healthy volunteer population does not establish efficacy or safety in actual AD patients. Primary outcomes are safety and tolerability only; no cognitive or biomarker endpoints reported here.
This is a preclinical safety and pharmacokinetic study in healthy older adults, not a demonstration of efficacy in disease. Results are needed to determine whether BNC is safe enough to advance to patient trials in Alzheimer's disease.
Phase 1 healthy volunteer safety study with completed enrollment but no posted results in registry; cannot assess efficacy or clinical benefit.
As stated by the source record.
Quoted from the source exactly as published.
This is a preclinical safety and pharmacokinetic study in healthy older adults, not a demonstration of efficacy in disease. Results are needed to determine whether BNC is safe enough to advance to patient trials in Alzheimer's disease.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT01747213). This is a study registration, not published results. Lead sponsor: National Institute on Aging (NIA). Recruitment status: COMPLETED. Phase: PHASE1. Study type: INTERVENTIONAL. Enrollment: 75 participants (ACTUAL). Conditions: Healthy Volunteers. Interventions: DRUG: BNC; OTHER: Placebo. Primary outcome measures: Safety and Tolerability , Will be completed in one year. Brief summary: Background: \- Alzheimer s disease (AD) is a brain disease that impairs memory, cognitive abilities and the ability to function independently. It is the most common cause of dementia in older people. It is caused by abnormal proteins in the brain that affect how neurons communicate with each other. Researchers are looking for drugs that can slow down the disease or treat its symptoms. One drug, called bisnorcymserine (BNC), may help improve brain function and symptoms in people with AD. BNC is designed to block a chemical that affects how neurons communicate with each other. Researchers want to see how BNC works in healthy older volunteers. Objectives: \- To look at how the body processes bisnorcymserine taken by mouth and how safe it is for healthy older volunteers. Eligibility: \- Healthy volunteers at least 55 years of age. Design: * Participants will be screened with a physical exam, medical history, and blood and urine tests. * Within 3 weeks from the screening visit, participants will come to the National Institute on Aging clinical unit for a 2-night stay. On the morning of the second day, they will take either a BNC capsule or a placebo. They will not know which tablet they are taking. * Blood samples will be collected frequently throughout the second and third days of the study visit. The last blood sample will be collected about 32 hours after taking the study capsule. Participants will have heart function tests and other exams during the visit. Once the tests are done, they will leave the clinical center. * Participants will have a final follow-up visit about 1 week after leaving the clinical center.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.